Pfizer has filed a lawsuit against Novo Nordisk and Metsera in an attempt to force through its takeover of the weight-loss drug developer and prevent Novo Nordisk from taking its rival bid forward.

Faced with soaring demand for leucovorin for use in children with autism, the American Academy of Paediatrics (AAP) has said ...

Welcome back to Changing Faces, in our final round-up for August and September there are plenty of Board appointments to ...

As drug development becomes more complex, so do the demands for accurate, reproducible bioanalytical data to prove their ...

Electra Therapeutics has garnered the funds it needs to complete a pivotal trial of its lead drug, angling to become the ...

Final draft guidance on NHS use of the drug marks a "significant shift" from NICE's 2021 decision on the drug as a first-line ...

Kennedy suggested the requirement for CES is one reason why the US is lagging behind other parts of the world in the rollout ...

CSL's already depressed share price sank further on the news of the delay, which chairman Dr Brian McNamee said was related ...

As clinical momentum grows for novel DDR targets such as ATR, CHK1/2, WEE1, and DNA-PK, this forum delivers a front-row seat ...

ESMO 2025 showcased the breadth and urgency of breast cancer research, which remains one of the most diagnosed malignancies ...

That is a sizeable increase on Pfizer's September offer of $47.50 upfront and $22.50 in CVRs, which combined to give a deal ...

BBP-418 hit the mark in the phase 3 FORTIFY trial by achieving a significant increase in glycosylated alpha-dystroglycan (αDG ...